Literature DB >> 27523265

Impact of Intramyocardial Hemorrhage and Microvascular Obstruction on Cardiac Mechanics in Reperfusion Injury: A Speckle-Tracking Echocardiographic Study.

Hang Zhao1, Alex Pui-Wai Lee2, Zheng Li1, Zhiqing Qiao1, Yiting Fan1, Dongaolei An1, Jianrong Xu1, Jun Pu1, Xuedong Shen1, Heng Ge1, Ben He3.   

Abstract

BACKGROUND: Intramyocardial hemorrhage (IMH) and microvascular obstruction (MVO) are two major mechanisms of reperfusion injury of the left ventricle after acute ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess the impact of IMH and MVO on left ventricular (LV) cardiac mechanics using two-dimensional speckle-tracking echocardiography during the acute phase of STEMI and on LV functional recovery.
METHODS: Eighty-one patients with STEMI who received primary reperfusion therapy were prospectively studied. Infarct segments were classified by cardiac magnetic resonance according to infarct transmurality and the presence or absence of IMH and/or MVO. Segmental systolic longitudinal strain, circumferential strain (CS), and radial strain were measured by two-dimensional speckle-tracking echocardiography. Adverse LV remodeling and major adverse cardiovascular events were assessed at 1 year.
RESULTS: MVO without IMH was much less frequent in nontransmural infarct segments than in transmural infarct segments (6.0% vs 19.1%, P = .000), while IMH was present only in transmural infarct segments. In nontransmural infarct segments, MVO was not associated with any significant changes in strain (P > .5). In transmural infarct segments, there were no differences in all types of strain between segments without reperfusion injury and those with MVO alone (P > .20). IMH was evident in the midmyocardial layer within the infarct zone in 196 segments (46.1%). The presence of IMH in addition to MVO decreased CS significantly (P = .004), but not longitudinal and radial strain (P > .5). A receiver operating characteristic curve analysis with cross-validation by k-folding showed that the sensitivity and specificity of CS using a cutoff of >-11.66% to diagnose IMH were 78.00% and 79.45%, respectively (area under the curve = 0.86; P = .0001). At 1 year, patients with major adverse cardiovascular events and LV remodeling had significantly lower baseline measurements of all types of global strain (P < .05).
CONCLUSIONS: In the acute phase of STEMI, reperfusion MVO and IMH injury have differential effects on cardiac mechanics. IMH preferentially affects CS, presumably related to its location in the midmyocardial layer.
Copyright © 2016 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2D speckle tracking echocardiography; Cardiac magnetic resonance (CMR); Intramyocardial hemorrhage (IMH); Microvascular obstruction (MVO); ST-segment elevation myocardial infarction

Mesh:

Year:  2016        PMID: 27523265     DOI: 10.1016/j.echo.2016.06.011

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  3 in total

1.  Low-dose dobutamine cardiovascular magnetic resonance segmental strain study of early phase of intramyocardial hemorrhage rats.

Authors:  Rui Xia; Bo He; Tong Zhu; Yu Zhang; Yushu Chen; Lei Wang; Yang Zhou; Jichun Liao; Jie Zheng; Yongmei Li; Fajin Lv; Fabao Gao
Journal:  BMC Med Imaging       Date:  2021-11-20       Impact factor: 1.930

Review 2.  Strain Imaging for the Early Detection of Cardiac Remodeling and Dysfunction in Primary Aldosteronism.

Authors:  Yilin Chen; Tingyan Xu; Jianzhong Xu; Limin Zhu; Dian Wang; Yan Li; Jiguang Wang
Journal:  Diagnostics (Basel)       Date:  2022-02-20

3.  Comparison of Diagnostic Value Between STE+LDDSE and CMR-FT for Evaluating Coronary Microvascular Obstruction in Post-PCI Patients for STEMI.

Authors:  Tao Liu; Chaofan Wang; Jie Yin; Lili Wang; Haochen Xuan; Yan Yan; Junhong Chen; Jieli Bao; Dongye Li; Tongda Xu
Journal:  Ther Clin Risk Manag       Date:  2022-08-15       Impact factor: 2.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.